Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Novavax is a clinical-stage biopharmaceutical company developing recombinant vaccines using a proprietary Virus-Like Particle (VLP) platform. Key product candidates include vaccines for pandemic influenza (H5N1, H1N1), seasonal influenza, and Respiratory Syncytial Virus (RSV). The company operates a cGMP manufacturing facility in Rockville, Maryland, and maintains a joint venture in India with Cadila Pharmaceuticals.
Key Financial Metrics
Note: Financial data for 2009 and 2008 has been restated due to the reclassification of warrants from equity to liability.
| Financial Metric (in thousands) | 2010 | 2009 (Restated) | 2008 (Restated) |
|---|---|---|---|
| Revenue | $343 | $325 | $1,064 |
| Net Loss | $(35,708) | $(40,346) | $(34,511) |
| Loss Per Share (Basic & Diluted) | $(0.34) | $(0.47) | $(0.51) |
| Cash and Cash Equivalents | $8,061 | $38,757 | $26,938 |
| Short-Term Investments | $23,615 | $4,193 | $33,900 |
| Total Current Assets | $33,337 | $44,503 | $35,096 |
| Working Capital | $23,071 | $36,476 | $7,379 |
| Warrant Liability | $2,842 | $4,513 | $2,541 |
| Long-Term Debt | $320 | $406 | $480 |
Cash Flow Summary (2010): Net cash used in operating activities was $32.9 million. Net cash used in investing activities was $21.3 million (primarily purchases of short-term investments). Net cash provided by financing activities was $23.4 million (primarily from stock sales).
Material Changes vs. Prior Period
- Restatement of Financials: The company restated financial statements for 2008 and 2009 following an SEC comment letter. Warrants issued in 2008 were reclassified from equity to a liability. Changes in the fair value of these warrants are now recorded in the statement of operations. This resulted in a $1.7 million gain in 2010 (reduction in liability) compared to a $2.0 million loss in 2009.
- Revenue: Revenue remained flat at approximately $0.3 million for 2010 and 2009, a significant decrease from $1.1 million in 2008 due to the timing of government contract work.
- Operating Expenses: Total operating expenses increased to $38.8 million in 2010 from $37.7 million in 2009. Research and Development (R&D) expenses rose 9% to $28.0 million, driven by higher employee costs and clinical trial support. General and Administrative (G&A) expenses decreased 9% to $10.8 million due to lower professional fees.
- Liquidity: Cash and cash equivalents decreased significantly from $38.8 million in 2009 to $8.1 million in 2010, while short-term investments increased to $23.6 million.
Guidance, Outlook, and Risks
Management Commentary and Outlook:
- HHS BARDA Contract: In February 2011, Novavax was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) valued at $97 million for a 36-month base period, with an option for an additional $82 million. This cost-plus-fixed-fee contract supports the development of seasonal and pandemic influenza vaccines.
- Licensing: In February 2011, the company entered a licensing agreement with LG Life Sciences (LGLS) for influenza vaccines in South Korea and other emerging markets, including upfront payments and royalties.
- Clinical Progress: The company completed Phase II trials for H1N1 and seasonal influenza in 2010 with positive safety and immunogenicity results. Phase I trials for RSV began in December 2010.
- Capital Resources: Management believes current cash, investments, and anticipated revenue from the BARDA contract and At-the-Market (ATM) stock sales are sufficient to fund operations for at least the next 12 months.
Risks and Contingencies:
- Internal Controls: The company identified a material weakness in internal controls over financial reporting regarding the accounting for complex derivative instruments (warrants). An adverse opinion was issued by auditors on internal controls.
- Profitability: The company has a history of losses with an accumulated deficit of $310.3 million. It expects to continue incurring significant operating losses as it advances clinical trials.
- Liquidity of Investments: The company holds $5.1 million in auction rate securities (fair value $4.1 million) which may be difficult to liquidate at acceptable prices due to credit market conditions.
- Related Party Litigation: Two former directors have defaulted on promissory notes totaling approximately $2.0 million. The company is pursuing legal action for collection.
Investor Verification Checklist
- Restatement Impact: Verify the specific impact of the warrant liability reclassification on historical earnings per share and equity balances.
- BARDA Contract Terms: Review the specific milestones and reimbursement rates under the $179 million potential BARDA contract to assess revenue recognition timing.
- Cash Burn Rate: Monitor the monthly cash burn rate given the reduction in cash equivalents to $8.1 million and the reliance on future financing or contract billings.
- Internal Control Remediation: Assess the progress of remediation plans for the material weakness in internal controls over financial reporting.
- Auction Rate Securities: Evaluate the liquidity risk and potential valuation adjustments for the $5.1 million holding in auction rate securities.
- Clinical Trial Data: Review the full data sets from the completed H1N1 and seasonal influenza Phase II trials to gauge regulatory approval prospects.